Multiple sclerosis (MS) is a chronic central nervous system disease featuring exacerbations of inflammation and demyelination that cause progressively debilitating clinical effects over time. Current treatments for multiple sclerosis are limited in their ability to impact overall disease progression. Research aimed at generation of novel potential therapeutics for MS is needed. Recently, kallikrein 6 (KLK6), a member of the kallikrein (KLK) family of secreted serine proteases, was found to be elevated in the cerebrospinal fluid and brain of MS patients. The fifteen known tissue-based KLKs cleave proteins through a similar mechanism, but have different binding pocket specificity, diverse localization in human tissues, and multiple biological functions. KLKs have been linked to normal human physiology (e.g. KLK4, enamel formation) and disease (e.g. KLK3, prostate cancer). KLK6 is one of the highest expressed serine proteases in the healthy human brain and is expressed predominately in mature oligodendrocytes in both human and mouse brain. The role of KLK6 in oligodendrocyte maturation, myelination, and disease is not fully understood. To evaluate the role of KLK6 in oligodendrocyte maturation, I used a pluripotent in vitro primary cell system to assess the impact of exogenous KLK6 and modulators of the KLK6 pathway on oligodendrocyte maturation. I demonstrate that signaling through KLK6 decreases the number of mature oligodendrocytes in culture, whereas blockade of KLK6 signaling increases the number of mature oligodendrocytes in culture in the presence of triiodothyronine higher than either agent alone. This work suggests that KLK6 modulation impacts oligodendrocyte maturation. To understand the potential impact of KLK6 pathway inhibition on remyelination, I used the toxin cuprizone to induce demyelination in mice. I found that animals treated with a KLK6 inhibitor had increased myelin staining in the corpus callosum compared to vehicle-treated. This work suggests that KLK6 modulates oligodendrocyte maturation and myelination and may be relevant for improving myelin-related therapeutic outcomes, particularly in multiple sclerosis. / 2019-06-12T00:00:00Z

No description available.

No description available.

Myelin damage is known to increase in the normal aging brain and to correlate with age-related cognitive decline. While the causes of increased myelin damage are unknown, here we consider whether the brain’s innate capacity for remyelination diminishes with age and hence could contribute to myelin damage through slow accumulation of myelin defects. Maintenance and repair of myelin depends upon oligodendroglia precursor cells (OPCs), which must differentiate into a sufficient number of healthy mature oligodendroglia (oligos), the myelinating cell of the brain. The extracellular matrix molecule hyaluronic acid (HA) has been shown to inhibit maturation of OPCs into mature myelinating oligos. The present study examined aging changes in myelination using four markers: the damaged myelin basic protein (dMBP) antibody, a histochemical reaction to stain HA, and immunohistochemistry for OPCs and mature oligos. These markers were quantified using cell density (oligos and OPCs), percent area stained (HA and dMBP), and fluorescence intensity (HA and dMBP). Relationships between these markers, age, and behavioral measures of cognitive function were investigated using single and multiple regression analyses. Results showed that in the corpus callosum and cingulum bundle of the rhesus monkey, staining for dMBP as a marker of myelin damage strongly correlated with increases in HA. The increase in HA in the cingulum bundle correlated positively with age. OPC density increased with age in both the cingulum bundle and corpus callosum. Mature oligo density did not change significantly with age, but approached a significant increase in the cingulum and approached a significant decrease in the corpus callosum. The increase in OPC density correlated positively with both HA and dMBP in the cingulum bundle. These data are consistent with the hypothesis that HA accumulation contributes to myelin damage by inhibiting the differentiation of OPCs into mature oligodendrocytes, diminishing the brain’s innate capacity for remyelination with age.

A key problem in multiple sclerosis (MS) is the diminished capacity for myelin repair. Although oligodendrocyte (OL) precursors can be seen at the lesion site, their ability to differentiate appears inhibited. MicroRNAs are key regulators of OL differentiation, and have been observed to be misregulated in MS lesions compared to healthy white matter. Thus, aberrant microRNA expression in MS lesions may disrupt the ability of incoming oligodendrocyte progenitor cells (OPC s) to differentiate. Specifically, a microRNA known as miR - 145 is downregulated as OPCs progress to OLs, but is found at unusually high levels in MS lesions. In this study, we investigated how misregulation of miR - 145 affects OL differentiation in vitro. Bioinformatic analysis revealed that putative targets of miR - 145 are significantly enriched for factors which promote actin cytoskeleton organization and myelination. An immortalized OL cell line was transduced with an inducible lentivirus to create stable lines that overexpress miR - 145. These stable lines were characterized while proliferating, early in differentiation and late in differentiation. Immunofluorescence was used to quantify changes in proliferation rate, apoptosis, branching ability and myelin gene expression. qPCR arrays were used to quantify changes in microRNA target expression levels between induced and uninduced cells. Two stable lines were created: ON - 145 - 1 and ON - 145 - 2, which upon induction, over - express miR - 145 ~33 - fold and ~11 - fold, respectively. When proliferating, no significant morphological differences nor target expression differences could be detected between induced and uninduced cells. Proliferation was significantly decreased in ON - 145 - 1 induced cells, but not in ON - 145 - 2. No changes in apoptosis frequency were detected. In contrast, during early and late differentiation, both induced cell lines showed significant morphological defects characterized by a reduction in both iii primary and secondary branching. Further, significant differences in branching ability were observed between induced cells of ON - 145 - 1 and ON - 145 - 2, suggesting a dose - dependent response to miR - 145 overexpression. Expression of MAG, a myelin marker, was also significantly lowered in induced cells of both cell lines. Finally, we found that multiple miR - 145 targets involved in promoting cytoskeletal organization and myelination were significantly decreased both early and late in differentiation. These results suggest that overexpression of miR - 145 during OL differentiation may disrupt actin organization and myelin gene expression required for successful process extension and subsequent myelinating ability. Thus, the increase in miR - 145 in MS lesions may be a significant contributing factor to the loss of myelin repair in MS lesions.

Multiple Sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. MS is caused by the immune-mediated destruction of myelin and oligodendrocytes, resulting in demyelination and neurodegeneration. The microRNA miR-145-5p has been demonstrated to be upregulated in MS lesions. Our lab has previously shown that dysregulation of miR-145-5p can interfere with oligodendrocyte differentiation in mice and that knockout of miR-145-5p protects mice from experimental autoimmune encephalomyelitis (EAE), a model for MS. The objective of this study is to determine if inhibition of miR-145-5p with an antisense oligonucleotide (ASO) is sufficient to protect mice from EAE. Female mice were induced with EAE and then treated with a control or miR-145 ASO at the onset of disease. We evaluated disease progression by monitoring clinical severity, and evaluating molecular and structural characteristics of EAE by RT-qPCR, histology, immunohistochemistry and electron microscopy. We have shown that the miR-145 ASO reduced miR-145-5p expression in the lumbar spinal cord, spleen and thymus following EAE induction. Treatment with the miR-145-5p ASO resulted in improved clinical severity of EAE, reduced neuroinflammation and increased myelination. Inhibition of miR-145-5p may represent a novel treatment for MS.

La sclérose en plaques (SEP) est une maladie démyélinisante dont les causes ne sont pas encore bien élucidées. Cependant, l’implication des réponses auto-immunes dans la mort des oligodendrocytes engendrant la destruction des gaines de myéline et le disfonctionnement axonal est bien documentée. Les thérapies actuelles utilisant des agents anti-inflammatoires et immunomodulateurs ciblent la réduction de l’inflammation et la progression de la maladie, mais leur efficacité reste limitée et décroit après un long traitement. Toutefois, une nouvelle stratégie de traitement, basée sur la capacité endogène du cerveau à réparer la myéline, commence à voir le jour.L’utilisation des hormones stéroïdes offre une grande opportunité, compte tenu de leurs actions pléiotropiques à la fois au cours du développement et chez les sujets adultes. Notre étude montre que les androgènes et les progéstagènes jouent un rôle très important dans la prolifération des oligodendrocytes et dans la réparation de la myéline. Ces stéroïdes permettent une remyélinisation au niveau des cultures organotypiques du cervelet de souris ou de rats après une démyélinisation par la lysolécithine. En outre, l’utilisation des souris knock-out pour le récepteur de la progestérone (PR-KO) montre l’importance de ce récepteur dans l’effet promyélinisant de la progestérone. De même, l’effet pro-remyélinisant des androgènes passe par l’intermédiaire de leur récepteur nucléaire (AR) puisque la Flutamide, agent antagonisant ces récepteurs, aboli complétement cette action. De même, l’utilisation des souris knock-out pour le récepteur de la progestérone montre l’importance de ce récepteur dans l’effet promyélinisant de la progestérone.L’influence de la testostérone et des ces métabolites sur la réparation de la myéline au niveau du corps calleux est aussi montrée in vivo, en traitant les souris C57Bl/6 par la cuprizone pendant 12 à 14 semaines. Le traitement de ces souris par la testostérone ou ces métabolites 5α- dihydrotestosterone (5α-DHT), 17β-estradiol ou par un agoniste synthétique fort, le 7α-methyl-19-nortestosterone (MENT) pendant 6 semaines, induit un remarquable recrutement des progéniteurs d’oligodendrocytes, suivie par une importante remyélinisation des zones démyélinisées. Le mécanisme d’action de ces androgènes implique le récepteur AR puisque aucun effet promyélinisant n’a été observé chez les souris dont l’AR est muté (tfm : testicular feminization mutation) et les souris ARNes/cre (mutation conditionnelle de l’AR dans les neurones et les cellules macrogliales). Les souris ArKO (Aromatse Knoctout) ne pouvant pas convertir la testostérone en estradiol sont aussi insensibles au traitement par la testérone.Ces travaux montrent que les stéroïdes jouent un rôle très important dans la remyélinisation in vitro et in vivo, fournissant une preuve expérimentale pour une utilisation des stéroïdes dans des essais cliniques futurs visant à réparer la myéline. / Multiple sclerosis (MS) is a very prominent demyelinating disease. The cause of demyelination in MS is not clear, however, it involves autoimmune responses and the death of oligodendrocytes accompanied by myelin destruction and axonal dysfunction. Currently available therapies including anti-inflammatory agents and immunomodulators are targeted to reduce inflammation and disease progression but their limited efficacy further decrease after prolonged treatment.However, another therapeutic strategy has gained recently much interest, is to boost the endogenous capacity of the brain to repair myelin.Steroid hormones offer an opportunity for therapeutic interventions in a wide range of tissue abnormalities because of their multiple actions during development and in adulthood. Our studies show that androgens and progestagens play pivotal role in oligodendrocyte proliferation and subsequent myelination. Androgens or progestagens promote remyelination after lysolecithin mediated myelin insult of organotypic cerebellar slices in culture. Moreover, remyelinating effects of testosterone can be blocked by flutamide, an androgen receptor (AR) inhibitor. Also, the remyelination induced by progestagens is abolished when cerebellar slices are used from progesterone receptors (PR) knockout mice.The influence of testosterone and its metabolites on myelin repair was also evident in toxininduced demyelination in vivo. Long-term cuprizone intoxication (12-14 weeks) of adult C57Bl/6 mice caused chronic and severe demyelination in the corpus callosum. Treatment of these mice with testosterone or its metabolites, particularly 5α-dihydrotestosterone (5α-DHT), estradiol-17β and potent testosterone analog 7α-methyl-19-nortestosterone (MENT) for 6 weeks results in a marked replenishment of the corpus callosum with oligodendrocytes and remyelination. Testosterone fails to stimulate remyelination in mice carrying testicular feminization mutation (Tfm) of AR in the cuprizone model. Furthermore, we demonstrate that testosterone directly targets neuronal and macroglial AR, because the specific ablation of neural AR in (ARNes/Cre) mice prevents the myelin repair in response to testosterone. Interestingly, blocking the conversion of testosterone into estrogens by knocking out the aromatase gene (ArKO mice), also impair the remyelinating effect of testosterone.In conclusion, we provide a strong evidence for a new role of progestagens and androgens in remyelination and thus present a sound experimental support for future clinical trials based on steroid hormone therapy for demyelinating disorders.

No description available.

Multiple Sclerosis (MS) is an inflammatory disease which causes areas of demyelination in the Central Nervous System (CNS) and affects only humans. Current therapies for MS are focused on anti-inflammatory treatment, which reduce the occurrence and clinical relapses of the disease. However, progressive disability of the disease is related to axonal degeneration. After demyelination, remyelination occurs, which helps repair the demyelinated lesions and protects axons from degeneration. However, this endogenous remyelination is inefficient, and currently there are no therapies available to enhance remyelination. The aim of this thesis was to first characterize a fast and reliable model to study CNS remyelination in vitro, and second to investigate the role of semaphorin 3a (Sema3A) and semaphorin 3f (Sema3F) signaling in CNS remyelination. Various in vivo models have been developed to investigate the pathology of multiple sclerosis, and can be used to test remyelination therapies. However, in vivo models are expensive, animal- and time- consuming. Until now, there has been no well-characterized and robust in vitro model for remyelination study. In this thesis, an ex vivo slice culture system with mouse brain and spinal cord was developed, and characterized by immunofluorescent microscopy and transmission electron microscopy, for CNS remyelination study. Automated (re)myelinating quantification by image pro plus software was developed and validated to provide a fast and reliable way for testing factors that change remyelination efficiency. Two such factors are Sema3A and 3F, which were initially identified as axon guidance cues during development. Sema3A (repulsive) and 3F (attractive) were proved to play a role in oligodendrocyte precursor cell (OPC) migration during development, and hypothesized to be important in remyelination. In this thesis, I investigated the effects and mechanisms for this by adding recombinant SEMA3A or SEMA3F or by knockdown their obligatory receptors Neuropilin (Nrp) 1 and 2, using lentivirus induced miRNAi. Slice culture and primary OPC culture were used to determine the effect on OPC survival, migration, proliferation, differentiation and myelination.

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by demyelination and loss of oligodendrocytes (OLGs), the CNS myelin-producing cells. Thus, understanding the mechanisms that control OLG development can provide valuable knowledge regarding remyelination therapies for MS. This disease is thought to result from an autoimmune attack towards myelin. FTY720, an immunomodulator under evaluation for MS treatment is a sphingosine-1-phosphate (S1P) analog. We found before that S1P plays a crucial role in the NT-3-mediated survival of OLGs, an observation that led us to investigate whether FTY720 could have any effect on these cells. Our studies demonstrate that FTY720 indeed has a direct effect on OLG progenitors, protecting them from apoptotic death through a mechanism involving ERK1/2 and Akt activation. However, another key finding of our study was that this drug arrested OLG differentiation, an effect counteracted by NT-3 which not only enhanced the survival of OLG progenitors but also stimulated their maturation. Furthermore, NT-3 induced an increase in myelin basic protein (MBP) levels in the absence of effects on MBP gene promoter activation or mRNA expression. These observations suggested that NT-3 up-regulated MBP levels by a posttranscriptional mechanism raising the question of whether this neurotrophin could have a more general positive effect on the expression of other OLG proteins. In agreement with this idea, we found that NT-3 also induced the expression of the myelin proteins MAG and MOG. Additionally, [35S]-Methionine labeling indicated a 50% increase in de novo protein synthesis following only a 15 min exposure to NT-3. Such a rapid increase in protein synthesis reinforced the idea that NT-3 plays a crucial role regulating protein expression by posttranscriptional mechanisms. In support of this possibility, we found that NT-3 stimulated the phosphorylation of the initiation factor eIF4E and its inhibitory partner 4EBP1, both essential players in mediating cap-dependent protein synthesis. This stimulation involved the activation of ERK1/2 and PI3K/mTOR mediated signaling pathways. To our knowledge, this is the first study on the regulation of translation initiation in OLGs and the first report describing the potential role of NT-3 as an activator of initiation.